Related Experiment Video
Updated: Dec 22, 2025
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.8K
Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma.
Fabio Tirotta1, Carlo Morosi2, James Hodson3
1Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
Annals of Surgical Oncology
|May 6, 2020
Summary
Targeting solid tumor areas in retroperitoneal liposarcoma biopsies significantly improves diagnostic sensitivity for dedifferentiated liposarcoma (DDLPS). This enhanced accuracy is crucial for identifying patients who may benefit from neoadjuvant therapy.
Area of Science:
- Oncology
- Surgical Pathology
- Diagnostic Imaging
Background:
- Retroperitoneal dedifferentiated liposarcoma (DDLPS) diagnosis via biopsy has variable sensitivity.
- Accurate pretherapy diagnosis is essential for patients with high-risk grade 3 DDLPS who may benefit from neoadjuvant therapy.
Purpose of the Study:
- To determine if targeting solid tumor areas on percutaneous biopsy improves diagnostic sensitivity for retroperitoneal liposarcoma.
- To enhance the detection rates of DDLPS and high-grade DDLPS.
Main Methods:
- Retrospective analysis of percutaneous biopsy data from 2016-2019 compared to a previous series (2005-2016).
- Diagnostic accuracy was calculated, with specific comparisons made for DDLPS biopsies targeting solid components versus non-targeted biopsies.
Main Results:
- Overall biopsy concordance improved from 67% to 83%.
- Sensitivity for DDLPS diagnosis increased from 40% to 74%; for grade 3 DDLPS, sensitivity rose from 13% to 50%.
- Targeted biopsies achieved 100% sensitivity for DDLPS detection, compared to 10% for non-targeted biopsies.
Conclusions:
- Systematic targeting of solid tumor areas in biopsies significantly improves the detection of DDLPS and grade 3 DDLPS.
- This targeted approach reduces the risk of underdiagnosis, ensuring patients eligible for neoadjuvant chemotherapy receive timely treatment.
